Boston Scientific cuts 2026 guidance for third time this year

Boston Scientific reported Q3 revenue of $5.14B, up 1.5% YoY, with net income of $582M. The company reduced its 2026 revenue growth forecast to 4.25% from 5.5%-6.5% and adjusted EPS guidance to $3.16-$3.18. Challenges in Watchman and electrophysiology businesses, along with a cyberattack, impacted performance. The stock fell 7% to $42.02. The $14.5B Penumbra acquisition is now expected to close in early 2027.

Original reporting
Published Oct 28, 2026, 4:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Boston Scientific cuts 2026 guidance for third time this year — source image
Decision brief

The 30-second read

$BSXBearishHigh
01

Why it matters

The guidance reduction and operational disruption create immediate downside risk, but the delayed acquisition may free cash flow later.

02

Market read

First report of guidance cut and cyberattack loss; traders can act on the negative outlook.

03

What to watch

Potential cost‑saving measures and upcoming product launches could mitigate the revenue decline.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Boston Scientific disclosed Q3 results, a cyberattack loss, and delayed closing of its $14.5B Penumbra acquisition.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific cut its 2026 revenue and EPS guidance and reported a $150M cyberattack hit, driving the stock down ~7% at open.

Expected impact

likely further decline as investors price in weaker outlook and cyber risk

Evidence & confidence

The article provides the first disclosure of the guidance reduction and quantifies the cyberattack hit, both material to valuation.

Market effects

MedTech sector may face broader scrutiny as other device makers confront cyber risk and slower growth in electrophysiology.

U.S. healthcare stocks could see modest pullback in early trading.

Limited to U.S. markets; no immediate global ripple beyond investors tracking large‑cap medtech.

Counterpoint

The guidance cut may be overblown if the cyberattack impact is one‑off and the underlying product pipeline remains strong.

Key entities

  • Boston Scientific

    Medical device maker reporting guidance cut and cyberattack impact.

  • Penumbra

    Target of Boston Scientific's $14.5B acquisition, closing delayed to early 2027.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.